Aurinia Pharmaceuticals Inc. expected to post earnings of 22 cents a share - Earnings Preview

What happened

Aurinia Pharmaceuticals Inc. is expected to report results on November 2 for the quarter ending September 30, 2026. Six analysts expect revenue up 13.9% to $83.691 million and earnings of 22 cents per share.

Confirmed

Global impact / market context

If the company meets the 22 cents per share estimate, it would continue a string of recent quarters where actual earnings beat analyst expectations. That record helps explain the average buy rating and a median $18.00 price target, about 4.6% above the last close of $17.21.

Analyst inference

Analysts have not changed their mean earnings estimate in three months, suggesting stable expectations into the report. Revenue is forecast to grow 13.9% from a year earlier, so investors may compare the actual figures against these levels to judge whether the recent pattern of beating estimates continues.

Analyst inference

What to watch

1. Watch whether reported revenue reaches $83.691 million, the average estimate from six analysts, and whether earnings per share reaches 22 cents, the average analyst estimate from LSEG data. Confirmed
2. A useful check is whether the company again beats the earnings estimate, as it did in each of the last eight quarters shown, since repeated beats can shift how investors view the current 22 cents estimate. Proposed
3. Watch whether the actual results support the average buy rating, four buy or strong buy and two hold, and the $18.00 median price target, which is about 4.6% above the $17.21 last close. Analyst inference

Evidence

• Original source link unavailable